CIC
IBRX icon

Cutler Investment Counsel’s ImmunityBio IBRX Stock Holding History

Cutler Investment Counsel’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$978K Buy
111,698
+11,698
+12% +$88.5K 0.09% 90
2026
Q1 		$767K Buy
+100,000
New +$685K 0.08% 91

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Cutler Investment Counsel's IBRX Position: Q2 2026 in Review

Cutler Investment Counsel increased its ImmunityBio (IBRX) stake by 12% in Q2 2026, buying an estimated $88.5K and bringing the position to 111,698 shares worth $978K. The position accounts for 0.09% of the portfolio, ranked #90.

Cutler Investment Counsel first reported a position in IBRX in Q1 2026 and has held it in 2 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Cutler Investment Counsel held 111,698 shares of ImmunityBio worth $978K as of Q2 2026.
  • Cutler Investment Counsel bought 11,698 ImmunityBio shares in Q2 2026, an estimated $88.5K.
  • ImmunityBio made up 0.09% of Cutler Investment Counsel's portfolio in Q2 2026, its #90 holding.
  • Cutler Investment Counsel first reported a position in ImmunityBio in Q1 2026 and has held it in 2 quarters since.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Cutler Investment Counsel's 13F filing for Q2 2026, filed 14 Jul 2026.